Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.

As tightening policies cast a shadow over Chinese bioventures relying mainly on in-licensing and shed fresh light on the importance of proprietary development, the CEO of one innovation-focused venture shares his views on strategy in an exclusive interview.

Billed as BridgeBio in China, US-based and China-oriented biotech LianBio breaks a long hiatus in US listing for Chinese biotechs.

Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states.